Butyrate augments interferon-α-induced S phase accumulation and persistent tyrosine phosphorylation of cdc2 in K562 cells by Miyachi, T et al.
The interferons (IFNs) are cytokines that produce divergent
biological activities, including inhibition of viral replication and
suppression of tumour growth (Lengyel, 1982). There are two
types of IFNs that bind specific receptors (R) and initiate their
biological activities. Type I IFNs (a and  b) share the same
receptor, whereas type II IFN (IFN-g) uses its own receptor (Farrar
and Schreiber, 1993). IFN-a induces distinct sets of genes, which
possess interferon-stimulated response element (ISRE)-like DNA
sequences (Dale et al, 1989). Ligand-bound type I-receptors asso-
ciate with Jak1 and tyk2 protein tyrosine kinases (PTKs), which
subsequently phosphorylate signal transducer and activator of
transcription (Stat) proteins Stat1 and Stat2 (Leung et al, 1995;
Stahl et al, 1995; Yan et al, 1996). Phosphorylated Stats migrate to
the nucleus, bind to ISRE-like elements and stimulate transcrip-
tion immediately (Darnell et al, 1994).
Although IFNs have been used for anti-cancer therapy, the
mechanisms of their anti-proliferative effects remain to be further
defined. Apparently, IFN-a inhibits cell cycle progression in
various cancer cells (Gutterman, 1994). IFN-a induces G0/G1
arrest through the activation of the retinoblastoma protein (pRB)
by suppression of its phosphorylation and the down-regulation of
c-myc gene expression (Einat et al, 1985; Resnitzky et al, 1992). In
some other cells, IFN-a induces blockage of the cell cycle at G2/M
transition or prolongation of the S phase (Wadler and Schwartz,
1990; Oberg, 1992). So far, little is known about the mechanism
for these different effects of IFN-a on inhibition of cell cycle
progression. It has been reported that loss or inactivation of the
normal G1 checkpoint conferred by pRB is associated with the
IFN-a-mediated S phase accumulation (Qin et al, 1997). However,
most cancer cells have disruption of the G1 checkpoint and express
an intact IFN type I receptor, but IFN-a-induced S phase accumu-
lation is not common. Thus, an unidentified factor(s) appears to be
involved in biological effects of IFN-a. From the aspect of cancer
therapies, identification of the factors may greatly improve its
therapeutic effect of IFN-a. We report here that sodium butyrate
augmented IFN-a-induced accumulation of the S phase in human
chronic myelocytic leukaemia (CML) K562 cells. During accumu-
lation of cells in the S phase, tyrosine phosphorylation of cdc2
protein was sustained. The persistent phosphorylation of cdc2
correlated well with the accumulation of the S phase. In sharp
contrast, IFN-g neither affected tyrosine phosphorylation of cdc2
nor induced S phase accumulation. Considering that dephosphoryl-
ation of cdc2 is required for entry into the G2/M phase, its persis-
tent phosphorylation may be associated with accumulation of the S
phase. In addition, sodium butyrate similarly augmented the IFN-
a-induced accumulation of the S phase in human CML MEG-01
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Summary Interferon-a (IFN-a) is a clinically useful cytokine for treatment of a variety of cancers, including chronic myelocytic leukaemia
(CML). Most CML cells are sensitive to IFN-a; however, its biological effects on leukaemic cells are incompletely characterized. Here, we
provide evidence that IFN-a induces a significant increase in the S phase population in human CML leukaemic cell line, K562, and that the
S phase accumulation was augmented by sodium butyrate. In contrast, neither sodium butyrate alone, nor sodium butyrate plus IFN-g,
affected the cell cycle in K562 cells. These data suggest that the effect of sodium butyrate depended upon IFN-a-mediated signalling. The
ability of leukaemic cells to exhibit the S phase accumulation after stimulation by IFN-a plus sodium butyrate correlated well with persistent
tyrosine phosphorylation of cdc2, whereas treatment with IFN-g plus sodium butyrate did not affect its phosphorylation levels. Considering that
dephosphorylation of cdc2 leads to entry to the M phase, the persistent tyrosine phosphorylation of cdc2 may be associated with the S phase
accumulation induced by IFN-a and sodium butyrate. In addition, another human CML leukaemic cell line, MEG-01, also showed the S phase
accumulation after stimulation with IFN-a plus sodium butyrate. Taken together, our studies reveal a novel effect of sodium butyrate on the S
phase accumulation and suggest its clinical application for a combination therapy with IFN-a, leading to a great improvement of clinical effects
of IFN-a against CML cells.
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cells. Taken together, these results suggest that sodium butyrate
may increase the anti-proliferative effect of IFN-a on CML cells.
MATERIALS AND METHODS
Cell culture and reagents
Human CML cell lines K562 and MEG-01 were cultured in
Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco,
Grand Island, NY, USA) with 10% fetal calf serum (FCS). To
evaluate cell viability, dead cells were counted by trypan blue
staining method. Human IFN-a and IFN-g were kindly supplied
by Sumitomo Chemical Pharmacy and Shionogi Chemical
Pharmacy (Osaka, Japan), respectively. Sodium butyrate was
purchased from Sigma Chemical Co. (St Louis, MO, USA).
Cell cycle analysis
Cell cycle distribution was determined by staining DNA with
propidium iodide essentially as described (Adachi et al, 1994).
Briefly, cells were stained with propidium iodide (Sigma) and
passed through the beam of an argon ion laser turned to 585 nm
(FAC/Scan; Becton Dickinson). The resulting fluorescent signal
was amplified, recorded and analysed by using a NIH image
program for a DNA histogram.
Antibodies and immunoblotting
Western blot analysis was performed essentially as described
(Adachi et al, 1997). Briefly, cells were washed with cold
phosphate-buffered saline (PBS) and lysed in 500 ml of a buffer
containing 100 mM sodium chloride (NaCl), 2 mM EDTA, 10 mM
sodium orthovanadate, 1 mM phenylmethylsulphonyl fluoride
(PMSF), 1% NP-40 and 50 mM Tris (pH 7.2). Their protein
concentrations were analysed by the Protein Assay kit (BioRad)
and each lysate (1 mg/sample) was subjected to immuno-
precipitation with anti-cdc2 monoclonal antibody (Transduction
Laboratories). The immunoprecipitates were then subjected to
sodium dodecyl sulphate polyacylamide gel electrophoresis
(SDS-PAGE), followed by electrophoretical transfer to Immobilon
(Millipore). The blots were incubated with blocking buffer
containing 3% bovine serum albumin (BSA), 10 mM Tris (pH 8.2),
140 mM NaCl and 0.01% NaN3. Blots were then incubated with 
1 mg ml—1 of anti-cdc2 antibody for 2 h in washing solution (150
mM NaCl, 10 mM Tris (pH 7.5) and 0.01% Tween 20) with 3%
FCS, and developed by a standard enhanced chemiluminescence
(ECL) method (Amersham, Arlington Heights, IL, USA). After
stripping in stripping buffer containing 100 mM 2-mercap-
toethanol, 2% SDS and 62.5 mM Tris-HCl pH 6.7 for 0.5 h, the
same blot was subsequently incubated with anti-phosphotyrosine
4G10 antibody (UBI).
RESULTS
Effects of butyrate and IFN-a on K562 cells
A human CML cell line K562 is capable to undergo erythrocytic
differentiation by the stimulation with sodium butyrate (Anderson
et al, 1979). Treatment with 1 mM sodium butyrate increased
expression of glycophorin-A, a marker of erythrocytes, on K562
cells by 31% (Figure 1A). During differentiation of K562 cells
with sodium butyrate, their cell numbers gradually decreased
compared with control cells (Figure 1B). When K562 cells were
incubated with sodium butyrate for 5 days, their cell number was
reduced to 52.8% of that of control cells.
Next, we investigated effects of IFN-a on K562 cells. IFN-a is
known to suppress proliferation of various cancer cells, including
CML cells (Lengyel, 1982; Ozer et al, 1993). Cell growth curves
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Figure 1 Effect of IFN-a and sodium butyrate on cell proliferation and viability of K562 cells. (A) Expression of glycophorin, a marker for erythroid
differentiation, on K562 cells with (shaded) or without (open) 1 mM sodium butyrate. The results were obtained by a two-step reaction with an anti-glycophorin
monoclonal antibody (mAb) and a goat-anti-mouse phycoerythrin-labelled antibody. (B) K562 cells were treated with 600 IU ml–1 of recombinant human IFN-a
(m) or 1 mM sodium butyrate (l) for the indicated number of days. Treatment of K562 cells with IFN-a plus sodium butyrate greatly reduced cell proliferation
(s s). The growth curve of control K562 cells, which were cultured in 10% FCS, is also shown (n). The mean number of cells from three independent
experiments was plotted against the number of days. Standard error values are indicated. (C) No significant effect of IFN-a and sodium butyrate on cell viability
of K562 cells. K562 cells were treated with IFN-a alone (n n), sodium butyrate alone ( ) or IFN-a plus sodium butyrate (n) for the indicated number of days and
their cell viability was assessed by trypan blue exclusion assay. Cell viability of control K562 cells is also shown ( ). The mean numbers of the cells were
obtained from three independent experiments1020 T Miyachi et al
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of K562 cells cultured in medium containing IFN-a with or
without sodium butyrate are shown in Figure 1B. The treatment
with IFN-a alone slightly suppressed proliferation of K562 cells,
but addition of IFN-a plus sodium butyrate further suppressed it,
and their increase of cell number was mostly abolished (Figure
1B).
We investigated whether these reagents induced apoptotic cell
death of K562 cells. Trypan blue exclusion assay showed that the
treatments with IFN-a and/or sodium butyrate did not increase
loss of cell viability significantly (Figure 1C). The treatment of
K562 cells with IFN-a plus sodium butyrate for 5 days resulted 
in growth arrest; however, the treatment led to neither distinct
morphological changes characteristic of apoptosis (data not
shown) nor loss of cell viability.
Butyrate augments S phase accumulation by IFN-a
As shown above, the treatment with sodium butyrate plus IFN-a
inhibited proliferation of K562 cells, but had little effect on their
viability. This led us to consider whether the treatment might affect
cell cycle progression. Following treatments with either sodium
butyrate or IFN-a for 3 days, K562 cells were harvested and
subjected to cell cycle analysis. When K562 cells were cultured
with IFN-a, a slight but significant increase in the S phase cell
population was observed (S phase was 39.6 ± 2.0%) as shown in
Figures 2 and 4. Although sodium butyrate alone showed no
significant effect on the cell cycle in K562 cells (S phase was 
24.0 ± 0.8%), butyrate plus IFN-a treatment markedly increased
the S phase cell population (S phase was 52.5 ± 3.7%) compared
with the cell population treated with IFN-a alone. The S phase
increase was accompanied by a decrease in the percentage of cells
in the G1 phase (65% to 27%).
We next investigated the time-course of S phase accumulation
following the treatment with sodium butyrate plus IFN-a. As
shown in Figure 3, no obvious change was seen after 1 day of the
treatment, but the S phase population began to accumulate at 3
days, and a significant increase of S phase accumulation was seen
(214% of control) with a corresponding decrease in the G1 phase
(41.7% of control). By 5 days after the treatment, the percentage of
cells in the S phase was slightly decreased but still higher than that
of control cells. Similar results were obtained in three separate
experiments.
IFN-g had no effect on cell cycle in K562 cells
We also investigated whether IFN-g induces accumulation of the S
phase or affects the action of sodium butyrate in K562 cells.
Following treatment of K562 cells with IFN-g alone or IFN-g plus
sodium butyrate for 3 days, their cell cycle populations were
monitored. The IFN-g stimulations either with or without sodium
butyrate showed no significant changes in the percentages of cells
in the S phase and other cell cycle phases. When K562 cells were
cultured with IFN-g plus sodium butyrate, the percentage of cells
in the S phase was 23.1%, while the percentage of K562 cells
treated with IFN-g alone was 24.8% (Figure 4A). Thus, accumula-
tion of the S phase was specifically induced by IFN-a and
augmentation of S phase accumulation by sodium butyrate
depended upon IFN-a-mediated signalling.
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Figure 2 DNA histograms showing the cell cycle distribution of K562 cells. K562 cells untreated (control) or treated with IFN-a and/or sodium butyrate for 3
days were stained with propidium iodide and subjected to FACS analysis. Each of the cell cycle profiles contains the percentage of cells in different stages of
the cycle, which was evaluated with the NIH image analysis programS phase accumulation by butyrate and IFNa 1021
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Low serum concentration did not augment S phase
accumulation induced by IFN-a
As shown in Figure 1, the sodium butyrate treatment slightly
suppressed cell proliferation of K562 cells. The suppression might
affect the S phase accumulation by IFN-a. To exclude this possi-
bility, we investigated the effect on S phase accumulation induced
by IFN-a of culture in a medium containing 4% FCS. Culture of
K562 cells in 4% FCS-containing medium showed a growth curve
similar to that seen in their culture with 1 mM sodium butyrate.
After 3-day culture of K562 cells (2.0 ´ 105 cells ml—1), the 
cell density of K562 cells in 4% FCS-containing medium was 
4.1 ± 0.22 ´ 105 cells ml—1, while the density in sodium butyrate-
containing medium was 4.3 ± 0.35 ´ 105 cells ml—1. When K562
cells were cultured with 4% FCS plus IFN-a, their cell cycle popu-
lations (S phase was 43.3 ± 1.8%) exhibited a pattern similar 
to that seen in cells treated with IFN-a alone (S phase was 
39.6  ± 2.0%) as shown in Figure 4. Thus, augmentation of S phase
accumulation by sodium butyrate seemed not to be associated with
suppression of cell proliferation, but rather the augmentation
depended upon actions of sodium butyrate in a specific manner.
Persistent tyrosine phosphorylation of cdc2 by IFN-a
and butyrate, but not by IFN-g and butyrate
During progression of the cell cycle, 34 kDa protein kinase cdc2
and cyclin B play key roles in regulation of the cell cycle (Nurse,
1990). The level of cdc2 is constant throughout the cell cycle, but
its kinase activity is sharply periodic, rising to a peak at the G2/M
transition (Moreno et al, 1989). Activation of cdc2 kinase is
required for checkpoints preventing entry into mitosis before
completion of the S phase (Enoch and Nurse, 1990). The activa-
tion is determined by dephosphorylation of a tyrosine (Y15)
within its catalytic site (Gould and Nurse, 1989), which is brought
about by phosphatase cdc25 (Straufeld et al, 1991). To investigate
whether S phase accumulation induced by IFN-a plus sodium
butyrate is associated with regulation of cdc2 activity, tyrosine
phosphorylation levels of cdc2 were examined by Western blotting
using a monoclonal antibody that specifically binds to tyrosine
phosphorylated cdc2. When K562 cells were cultured with or
without IFN-a and/or sodium butyrate for 3 days, the treatment
with IFN-a increased the tyrosine phosphorylation level of cdc2,
and the level was the highest in K562 cells with IFN-a plus
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Figure 3 Time course of the S phase accumulation of K562 cells treated with IFN-a plus sodium butyrate. DNA histograms showing the cell cycle distribution
of K562 cells treated with both 600 IU ml–1 of IFN-a and 1 mM sodium butyrate for the indicated number of days. Each sample was stained with propidium iodide
and subjected to FACS analysis. Each of the cell cycle profiles contains the percentage of cells in different stages of the cycle, which was evaluated with NIH
image analysis
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Figure 4 Cell cycle distribution of K562 cells after treatment with IFN-a,
IFN-g and sodium butyrate. (A) The percentages of cells in different stages of
the cycle according to the cell cycle profiles of K562 cells treated with IFN-g
with or without sodium butyrate for 3 days. (B) Cell cycle distribution of K562
cells grown under various conditions for 3 days. K562 cells were cultured in
medium containing 4% FCS plus IFN-a, or treated with IFN-a and/or sodium
butyrate. Each bar contains G0/G1 (open column), S (closed column) and
G2/M (shaded column) phase populations. (C) The percentages of K562 cells
in the S phase under various conditions described in (B). The mean numbers
of their percentages were obtained from three independent experiments.
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sodium butyrate (Figure 5A). When the levels were normalized for
their protein amount, the levels of K562 cells treated with IFN-a
and IFN-a plus sodium butyrate were increased by 2.0-fold and
2.6-fold compared with control cells, respectively. The time-
course of tyrosine phosphorylation levels of cdc2 revealed that the
levels gradually increased by 3 days (Figure 5B). In contrast, the
treatment with IFN-g plus sodium butyrate did not affect the
tyrosine phosphorylation levels of cdc2 significantly (Figure 5C).
Butyrate also augmented IFN-a-induced S phase
accumulation in MEG-01
To explore whether sodium butyrate augments the IFN-a-induced
S phase accumulation in other CML cells, we investigated the
effect of sodium butyrate in MEG-01 cells, which have been estab-
lished from a patient with Philadelphia chromosome-positive
CML in blast crisis (Ogura et al, 1985). When MEG-01 cells were
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Figure 5 Tyrosine phosphorylation of cdc2. (A) IFN-a and sodium butyrate treatment sustained tyrosine phosphorylation of cdc2 in K562 cells. K562 cells
were cultured with or without IFN-a and/or sodium butyrate for 3 days, and tyrosine phosphorylation levels of their cdc2 were analysed. (B) Time-course of
tyrosine phosphorylation of cdc2. K562 cells were cultured with or without IFN-a and sodium butyrate for the indicated number of days. (C) IFN-g and sodium
butyrate treatment did not affect tyrosine phosphorylation of cdc2 in K562 cells. K562 cells were cultured with or without IFN-g alone or with sodium butyrate for
3 days, and tyrosine phosphorylation levels of their cdc2 were analysed. Total cell lysates were immunoprecipitated with an anti-cdc2 antibody and tyrosine
phosphorylation levels of the immunoprecipitates were analysed by immunoblotting using an anti-phosphotyrosine antibody 4G10 at 1 mg ml–1
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Figure 6 DNA histograms showing the cell cycle distribution of MEG-01 cells. MEG-01 cells untreated (control) or treated with IFN-a and/or sodium butyrate
for 3 days were stained with propidium iodide and subjected to FACS analysis. Each of the cell cycle profiles contains the percentage of cells in different stages
of the cycle, which was evaluated with the NIH image analysis programcultured with IFN-a, a slight but significant increase in the S phase
cell population was observed (S phase was 32.0%) as shown in
Figure 6. Sodium butyrate also showed a slight effect on the cell
cycle in MEG-01 cells (S phase was 29.7%), but the butyrate plus
IFN-a treatment markedly increased the S phase cell population (S
phase was 44.6%) compared with the cell population treated with
IFN-a alone. The S phase increase was accompanied by a decrease
in the percentage of cells in the G1 phase (63.7% to 36.6%). Thus,
the butyrate plus IFN-a treatment can increase the S phase cell
population of at least two CML cell lines.
DISCUSSION
In this report, we have shown that sodium butyrate augments 
IFN-a-induced S phase accumulation. Although sodium butyrate
reduced cell proliferation of K562 cells, this effect seemed to be
marginal with respect to its enhancement of IFN-a-induced S
phase accumulation, since reduced cell proliferation due to
incubation of K562 cells in medium containing a low FCS concen-
tration had no significant effect on IFN-a-induced S phase
accumulation. Although sodium butyrate can induce apoptosis in
many cancer cells (Calabresse et al, 1993; Hague et al, 1993;
McBain et al, 1996), this reagent neither induced nor augmented
apoptosis when co-incubated with IFN-a in K562 cells, at least
during incubation for 5 days. It is not clear how sodium butyrate
augments IFN-a-induced S phase accumulation. A previous report
showed a positive interaction between IFN-a and chemotherapy
(Balkwill et al, 1984). Cyclophosphamide, an alkylating agent,
caused accumulation in the G2 and S phases. The addition of IFN-
a with cyclophosphamide delayed the G2 block and markedly
increased the cell population in the S phase. Considering the effect
of alkylating agents as inhibitors of DNA synthesis, it is conceiv-
able that combination of cyclophosphamide with IFN-a increased
S phase accumulation. In contrast, there has been no report
suggesting that sodium butyrate is capable of inhibiting DNA
synthesis. Sodium butyrate is a short chain fatty acid produced by
bacterial degradation of poorly fermentable dietary fibres in the
colorectum (Reeder et al, 1993), and is known to inhibit splicing of
the c-myc gene (Krupitza et al, 1995) and several signal transduc-
tion pathways, i.e. inhibition of the release of Ca2+ from intracel-
lular stores and casein kinase II activity (Russo et al, 1997). Since
the treatment of K562 cells with sodium butyrate alone reduced
cell proliferation, the reagent may inhibit growth signals mediated
by FCS. However, exposure of K562 cells to sodium butyrate
alone did not affect the cell cycle significantly and its effect on S
phase accumulation totally depended upon IFN-a-mediated
signals. As IFN-a and sodium butyrate synergistically suppressed
the proliferation of K562 cells, they may cooperate with the func-
tion for suppression of cell cycle progression and cause accumula-
tion of the population in the S phase.
Sodium butyrate is an erythroid differentiation inducer of K562
cells. Thus, its augmentation of the S phase may be associated with
differentiation of K562 cells. To investigate this possibility, we
examined the cell populations of the cell cycle following treatment
with TPA, a megakaryocytic differentiation inducer for K562 cells.
TPA and/or IFN-a treatment had no significant effect on the S
phase population (data not shown). In HL60 cells, TPA and RA,
differentiation inducers of monocytes and myeloid cells, respec-
tively, could not augment S phase accumulation (data not shown).
Thus, differentiation events were not directly involved in the
augmentation of S phase accumulation, but rather a specific action
of the reagent might have been involved in the augmentation.
Thus, sodium butyrate is a unique differentiation inducer which
can augment S phase accumulation.
Early studies demonstrated that IFN-a induces G0/G1 arrest in
Daudi Burkitt￿s lymphoma or M1 myeloid cells (Einat et al, 1985;
Tiefenbrun et al, 1996). However, IFN-a also induces S phase
accumulation in a variety of cancer cells (Qin et al, 1997). Though
molecular mechanisms for these different effects of IFN-a remain
to be clarified, the G1 checkpoint function is thought to be a major
factor to determine different effects of IFN-a; G0/G1 arrest occurs
in cancer cells containing functional pRB, a key molecule for the
G1 checkpoint, whereas S phase accumulation occurs in cancer
cells lacking functional pRB. K562 cells are known to express
functional pRB, which is required for erythroid differentiation
(Bergh et al, 1997). This implies that IFN-a can induce S phase
accumulation even in cells expressing functional pRB.
Considering that K562 cells lack p53 expression (Sugimoto et al,
1992), the loss of p53 function is likely to induce uncontrolled
CDK activity, leading to aberrant phosphorylation of pRB, which
may explain why IFN-a induces S phase accumulation in K562
cells.
cdc2 plays key roles in regulation of the cell cycle and its
activity is predominantly regulated by tyrosine phosphorylation
levels (Gould and Nurse, 1989; Nurse, 1990). In the late G1 phase,
cdc2 is tyrosine phosphorylated by wee1 or mik1 (Featherstone
and Russell, 1991; Lundgren et al, 1991) and the phosphorylated
cdc2 is then dephosphorylated by cdc25 before entry into the
M phase (Straufeld et al, 1991). Thus, dephosphorylation of
cdc2 seems to be required for G2/M transition, though tyrosine
phosphorylation of cdc2 has not been demonstrated to cause S
phase arrest in mammalian cells (Sherr, 1993). To explore the
mechanisms of IFN-a-induced S phase accumulation and its
augmentation by sodium butyrate in K562 cells, we investigated
tyrosine phosphorylation levels of cdc2. The IFN-a treatment
inhibited dephosphorylation of cdc2, and IFN-a plus sodium
butyrate further inhibited the dephosphorylation, resulting in
persistent phosphorylation of cdc2. Considering the tight correla-
tion between S phase accumulation and elevated phosphorylation
levels of cdc2, it is conceivable that tyrosine phosphorylation of
cdc2 may be a target of IFN-a. This idea is supported by a recent
report that IFN-a can suppress cdc25 expression (Tiefenbrun et al,
1996), which is responsible for dephosphorylation of cdc2.
Alternatively, a target of IFN-a and sodium butyrate would be the
replication machinery and subsequently result in persistent tyro-
sine phosphorylation of cdc2, since cdc2 is known to be phos-
phorylated in response to DNA damage and may function to block
inappropriate entry into mitosis (Jin et al, 1996). In addition, the
IFN-a plus sodium butyrate treatment may inhibit the cell cycle
more generally, since the S phase accumulation (S phase cell popu-
lation was approximately 50%) appears not to fully explain the
complete loss of cell proliferation (Figure 1B), and cell population
at the G2/M phase also increased in response to the treatment.
Obviously, it is important to clarify the precise molecular
machinery of IFN-a-induced S phase accumulation and its
augmentation by sodium butyrate.
Our data clearly showed that sodium butyrate can enhance the
effect of IFN-a by augmentation of S phase accumulation. Though
sodium butyrate has very high toxicity in vivo, the effectiveness of
sodium butyrate derivatives for colon cancer patients is now under
S phase accumulation by butyrate and IFNa 1023
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investigation in extensive clinical trials. If a non-toxic derivative
of sodium butyrate is available, its combination with IFN-a may
greatly improve the anti-tumour effect of IFN-a.
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